News - Daiichi Sankyo


Current filters:

Daiichi Sankyo

Popular Filters

76 to 87 of 87 results

Backing for Japanese approval of Regnite, Ranmark and Cancidas


USA-based XenoPort (Nasdaq: XNPT) saw its shares rise 3% to $4.73 on Friday, when the company said it…

Antibiotics and Infectious diseasesAsia-PacificCancidasDaiichi SankyodenosumabHorizantMerck & CoOncologyPharmaceuticalRegniteRegulationXenoPort

Daiichi Sankyo to license ARQ 092 from ArQule, under joint AKIP research collaboration


Japanese drug major Daiichi Sankyo (TSE 4568) says it has executed a license agreement with USA-based…

ArQuleDaiichi SankyoLicensingOncologyPharmaceuticalResearch

Disappointing first-half FY 2011/12 results from Japanese drugmakers


There was a slew of financial results for the first half of fiscal year 2011 (to September 30, 2011)…

Daiichi SankyoDainippon Sumitomo PharmaFinancialMitsubishi TanabeNippon ChemipharPharmaceuticalShionogi

Daiichi Sankyo research exec points out “a lot of hype” around biomarkers


Robert Beckman, executive director, clinical development oncology at Japanese drug major Daiichi Sankyo…

Daiichi SankyoOncologyPharmaceuticalResearch

Daiichi Sankyo extends reach in Italy, with Ranbaxy to market its products


The Italian subsidiaries of Japanese drug major Daiichi Sankyo (TYO: 4568) and its majority-owned India-based…

Cardio-vascularDaiichi SankyoEuropeGenericsMarkets & MarketingRanbaxy Laboratories

Daiichi Sankyo admits supply problem with flu vaccine; gains approval for silodosin in China


Japanese drug major Daiichi Sankyo (TYO: 4568) announced this week that its domestic subsidiary, Kitasato…

Asia-PacificDaiichi SankyoMarkets & MarketingOncologyPharmaceuticalRegulationsilodosinVaccines

Takeda and Daiichi Sankyo both get Japanese government grants for vaccine facilities


Japan’s largest drug company Takeda Pharmaceuticals (TYO: 4502) and fellow major Daiichi Sankyo…

Anti-viralsAsia-PacificBaxter InternationalDaiichi SankyoFinancialPharmaceuticalTakeda Pharmaceuticals

Ranbaxy posts 2nd-qtr 2011 net profit down 25%


India’s largest drugmaker Ranbaxy (RANB: BO) reported second-quarter 2011 financial results, with…

Daiichi SankyoFinancialGenericsRanbaxy Laboratories

Daiichi Sankyo and Ranbaxy expand business in Mexico with launch of olmesartan


Japanese drug major Daiichi Sankyo (TYO: 4568) and its 64% owned Indian affiliate Ranbaxy Laboratories…

Cardio-vascularDaiichi SankyoGenericsMarkets & MarketingolmesartanRanbaxy LaboratoriesSouth America

First-quarter FY 2012 net profit at Takeda jumps 18%, while that at Daiichi Sankyo slumps 23.5%


There were mixed financial reports from Japanese drugmakers, with the country’s biggest, Takeda…

Daiichi SankyoFinancialPharmaceuticalRanbaxy LaboratoriesTakeda Pharmaceuticals

76 to 87 of 87 results

Back to top